当前位置: X-MOL 学术J. Infect. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study.
Journal of Infection ( IF 28.2 ) Pub Date : 2019-10-01 , DOI: 10.1016/j.jinf.2019.09.020
Pilar Garcia-Broncano 1 , Luz Maria Medrano 2 , Juan Berenguer 3 , Oscar Brochado-Kith 2 , Juan González-García 4 , Ma Ángeles Jiménez-Sousa 2 , Carmen Quereda 5 , José Sanz 6 , María Jesús Téllez 7 , Laura Díaz 8 , José Luis JIménez 9 , Salvador Resino 2 ,
Affiliation  

OBJECTIVE There are a lack of consistency among articles in regards to the evolution of peripheral immune biomarkers after HCV therapy. We aimed to detect the most relevant changes in peripheral immune biomarkers among HIV/HCV-coinfected patients who achieved sustained virologic response (SVR) following peg-IFN-α/ribavirin therapy and to evaluate its normalization with respect to an HIV-monoinfected control group. METHODS We performed a prospective cohort study in 99 HIV/HCV-coinfected patients with samples at baseline (HIV/HCV-b-group) and at week 24 after SVR (HIV/HCV-f-group). We also used a control group of 39 HIV-monoinfected patients (HIV-group) negative for HCV and HBV infections, and who had undetectable HIV viral load and CD4+ >500 cells/mm3. Peripheral T cell subsets were assessed by flow cytometry and plasma biomarkers by immunoassays. RESULTS HIV/HCV-coinfected patients had higher values of in IL-10, IL-4, IP-10, IL-8, IL-1β, IL-18, IL-6, IFN-γ, IL-12p70, TNF-α, sVCAM-1, sICAM-1, and sTNFR-1 than HIV control subjects, both at the beginning and at the end of follow-up. Moreover, three biomarkers (CD4+CD38+, telomere length, and IL-1RA) were normalized in relation to the control group at the end of follow-up (the HIV/HCV-b group had higher values and the HIV/HCV-f group had similar values as the HIV-group). Additionally, LPS, IL-2, and IL-17A levels were higher in the HIV/HCV-f group than the HIV-group (24 weeks after SVR). During the follow-up, HIV/HCV-coinfected patients had a significant decrease by the end of follow-up in CD8+CD45RA-CD28+, CD4+CD38+, CD4+CD25+CD127-/low, CD4+CD25+CD127-/low CD45RA-, FABP2, LBP, IP-10, sVCAM1. Only CD4+CD38+ was normalized. CONCLUSION HIV/HCV-patients showed a slight improvement in the overall profile of immune biomarkers after achieving SVR.

中文翻译:

前瞻性研究:HIV / HCV合并感染的丙型肝炎患者中丙型肝炎患者的免疫生物标志物的轻度改善。

目的关于HCV治疗后外周免疫生物标记物的进化,文章之间缺乏一致性。我们旨在检测在接受peg-IFN-α/利巴韦林治疗后获得持续病毒学应答(SVR)的HIV / HCV合并感染患者中,外周免疫生物标记物的最相关变化,并评估其相对于HIV单一感染对照组的正常化。方法我们对99例HIV / HCV合并感染的患者进行了一项前瞻性队列研究,这些患者在基线(HIV / HCV-b组)和SVR后第24周(HIV / HCV-f组)样本。我们还使用了39名HCV和HBV感染阴性,HIV病毒载量无法检测且CD4 +> 500细胞/ mm3的HIV单感染患者(HIV组)作为对照组。通过流式细胞术评估外周T细胞亚群,通过免疫测定法评估血浆生物标志物。结果HIV / HCV合并感染的患者的IL-10,IL-4,IP-10,IL-8,IL-1β,IL-18,IL-6,IFN-γ,IL-12p70,TNF-α的值较高在随访开始和结束时,与HIV对照受试者相比,α,sVCAM-1,sICAM-1和sTNFR-1更高。此外,在随访结束时,相对于对照组,三个生物标志物(CD4 + CD38 +,端粒长度和IL-1RA)已正常化(HIV / HCV-b组的值较高,HIV / HCV-f组与HIV组具有相似的价值)。此外,HIV / HCV-f组的LPS,IL-2和IL-17A水平高于HIV组(SVR后24周)。在随访期间,HIV / HCV合并感染的患者在随访结束时CD8 + CD45RA-CD28 +,CD4 + CD38 +,CD4 + CD25 + CD127- /低,CD4 + CD25 + CD127- /低CD45RA-,FABP2,LBP,IP-10,sVCAM1。仅将CD4 + CD38 +标准化。结论HIV / HCV患者在达到SVR后,免疫生物标志物的总体特征略有改善。
更新日期:2019-10-02
down
wechat
bug